The FYN Knockout Raji Polyclonal Cells product provides a CRISPR/Cas9-edited polyclonal knockout cell population in which the FYN gene has been disrupted. This loss-of-function model enables investigation of FYN-dependent signaling pathways in a B-lymphocyte context. The polyclonal format maintains a diverse population of gene-edited cells, reflecting heterogeneous knockout efficiencies and representing a practical tool for pooled functional assays without clonal selection.
The Raji cell line is a well-characterized human B lymphocyte, lymphoblastoid line derived from a Burkitt lymphoma patient. These cells exhibit robust B-cell receptor (BCR) surface expression and downstream signaling competence, making them an ideal host for studying antigen receptor-mediated signal transduction. Raji cells are widely used in immunology and cancer research to model B-cell activation, proliferation, and survival mechanisms, particularly in the context of lymphoma biology.
FYN encodes a non-receptor tyrosine-protein kinase of the SRC family. Upon BCR engagement, FYN is activated by the receptor-associated CD45 phosphatase and CSK kinase, leading to phosphorylation of immunoreceptor tyrosine-based activation motifs (ITAMs) on the Ig?? (CD79A) and Ig?? (CD79B) chains. This event recruits and activates SYK, which subsequently phosphorylates downstream adaptors and effectors, including BLNK, PLC??2, and the PI3K p85 regulatory subunit. FYN also interacts with scaffold proteins such as LAT and SLP-76, and contributes to the activation of the MAPK cascade (ERK and JNK), AKT, and NF-??B pathways. Thus, FYN serves as a critical proximal mediator of BCR signal propagation, integrating receptor-proximal events with downstream transcriptional and cytoskeletal responses.
In Raji cells, disruption of FYN is expected to impair BCR signal transduction, resulting in attenuated ITAM phosphorylation, reduced SYK and ERK activation, and diminished calcium flux. Given the role of tonic and antigen-dependent BCR signaling in lymphomagenesis and cell survival, FYN knockout may alter proliferation, apoptosis, and migratory properties of these Burkitt lymphoma-derived cells. This model is particularly relevant for exploring the signaling dependencies of B-cell malignancies and for validating FYN as a therapeutic target in lymphoma and autoimmune diseases where aberrant BCR signaling is implicated.
This product is suited for a range of advanced research applications, including dissection of BCR-proximal signaling mechanisms, pharmacological inhibition studies, and functional genomics screens. Researchers can employ Western blotting to assess FYN, phospho-ITAM, phospho-SYK, and phospho-ERK levels, flow cytometry to measure BCR expression and calcium flux, and cell-based assays for proliferation, apoptosis, and migration. Additionally, co-immunoprecipitation can be used to examine FYN interactions with LAT, SLP-76, or PI3K. The polyclonal knockout cells provide a versatile system for high-throughput drug sensitivity testing and for studying T-cell-independent B-cell responses. For further technical inquiries, please contact Ascent Research.
